Church & Dwight Co., Inc. (NYSE: CHD) — The Best Top Line in Staples, Bought With the Bottom One

An independent analyst’s report. Report date: 2026-08-15. Update to a prior note dated 2026-06-14. Fiscal year ends December 31. All figures USD unless noted.

⚡ Claude’s Take

This block is the author’s own subjective opinion. It is general information and not investment advice. The analytical body that follows carries no recommendation and no price target — by design.

Verdict: HOLD, and a slightly less comfortable one than two months ago — the operating result got worse while the price got higher. Fair-value zone ~$82–92 (≈16–18x EV/EBITDA on a realistically-taxed ~$1.35B, or ~23–25x a credible ~$3.65 adjusted EPS). At $101.30 I would not buy, would not short, and would want the low-$80s again before adding. The prior report’s ~$80–88 zone is nudged up to ~$82–92 — not because the business improved, but because the whole staples cohort re-rated and CHD is no longer the clear premium name in it.

Here is the tension in one line: Church & Dwight just printed the best organic growth in large-cap staples — +5.8%, with international +9.1% and TheraBreath taking 4.5 share points — and its adjusted earnings per share went down. Adjusted EPS was $0.89 against $0.94 a year ago; adjusted operating income fell $28.7M, or 9.1%; adjusted operating margin dropped ~220bps to ~18.8%. The “beat” against a $0.88 outlook was manufactured almost entirely by the tax line, which fell from 23.8% to 20.3% — at last year’s rate the quarter earns roughly $0.85 and misses. Across the first half, adjusted EPS is down 0.5% on organic growth of 5.4%. And yet management raised the full-year adjusted-EPS guide to +6–8%. Do that arithmetic and the fourth quarter has to deliver $1.01–$1.08 against $0.87 last year — up 16% to 24%, the largest year-over-year adjusted-EPS quarter in years, after a first half that went backwards. I believe roughly half of that is mechanically real (the Touchland cost drag anniversaries, the gross-margin bridge steepens, tax is lower), and I do not believe all of it. The market appears to agree: the stock rose 1.2% on a raised guide.

The second thing that changed is the incentive structure, and it is the part I like least. In January 2026 the board granted a one-time 2030 Strategy PSU — $5.0M at target and $7.5M at maximum for the CEO — tied to three equally weighted measures, all of which are net sales CAGR: Arm & Hammer, non-US, and oral care. The annual bonus runs on net sales, gross margin, adjusted EPS and cash flow. The regular PSUs run on relative TSR. There is no return-on-capital metric anywhere in this company’s compensation. At a firm that has written off $840M+ of acquired brands and watched ROIC fall from 16.7% to 13.0%, the largest new long-term award pays out on a number that acquisitions mechanically increase — and the CEO spent the Q2 call describing an international M&A engine that has gone “from first to third gear” after filtering 100 deals. Meanwhile Touchland, bought last year at ~7.6x sales for ~$870M all-in, is now guided to “high single digits” growth; Miss Mouth’s was added in May at ~4.1x sales; and the buyback — $900M in 2025 at $83–96 — was zero in the first half of 2026 at $93–103. Both the company and its insiders bought aggressively at $91–95 and have bought nothing since. That is not a statement about the business. It is a statement about the price, and it happens to be my statement too. Framing: a genuinely improving top line attached to an unimproving return on capital, at a price that already assumes both get fixed.

Conviction: medium. Flips bullish if Q4 lands at $1.00+ on operating leverage rather than tax — i.e. adjusted operating income actually grows — and management pairs it with a resumed buyback instead of a fourth acquisition. Flips bearish if Q4 misses into the $0.90s (forcing a full-year cut), if the Waterpik trade name — $644.7M carrying value with only 17% fair-value headroom on assumptions of “mid-single- to low double-digit revenue growth” for a business the 10-Q describes as declining — takes its charge in the Q4 test, or if the next international deal is struck at a Touchland multiple. Tag: “Winning the share war, losing the margin war, paying for both.”

📈 Stock Price Action — Five-Year Event Map

Over five years CHD has round-tripped and then some: from ~$102 at the end of 2021, down to a $70.72 low on 2022-10-07, up to a $113.20 high on 2025-03-10, down again to ~$81.60 in late 2025, and back to $101.30 on 2026-08-14 — 8.8% below its five-year high, inside a 52-week range of $81.60–$105.26. Three full drawdown-and-recovery cycles in five years, with a five-year annualised return of ~5.1% and a three-year annualised return of ~3.3%. The compounding has been in the narrative, not in the price.

Cycle narrative. (1) The 2022 derating was an input-cost event: oil-linked surfactants and resins compressed gross margin to 41.9% from 45.2% in 2020, and the 2022-07-29 second-quarter print produced the single worst day of the five years, −8.6%. (2) The 2022–23 recovery was pricing catching up to cost, confirmed by the +5.8% reaction on 2023-04-27. (3) Through 2023–24 the stock re-rated on a defensive bid and two solid organic years, peaking at $113.20 in March 2025. (4) The 2025 decline was fundamental and self-inflicted: organic growth collapsed to ~0.7%, and the year was spent writing down and exiting Flawless, Spinbrush, Waterpik showerheads and the vitamins business — the 2025-05-01 exit announcement took 7.0% off in a day. (5) The +7.2% day on 2025-10-31 came at the bottom, on a Q3 print that credited the cleanup — and it is the same window in which the CEO, CFO and EVP International were buying stock personally and the company was repurchasing $900M of its own. (6) 2026 has been the recovery of that discount on two strong organic quarters. (7) Notably, the most recent leg has not been earnings-driven: the Q2 print that raised full-year sales, EPS and cash-flow guidance moved the stock only 1.2%, and the last three months delivered ~+8.0% against a six-month return of roughly zero. Price moves are Facts; the attributed causes are Interpretation.

Changes Since 2026-06-14

Five things moved the thesis in the nine weeks since the prior report; two of them cut against the prior report’s own reasoning, and this update says so plainly.

1. The organic reacceleration is real and is no longer explainable by an inventory comparison. Q2 FY2026 organic sales grew +5.8% (volume +4.3%, price/mix +1.5%), broad-based across Domestic +5.1%, International +9.1% and SPD +2.8%. The prior report correctly discounted Q1’s +5% because roughly two points were a year-ago inventory tailwind. That caveat does not apply to Q2, and management confirmed consumption and organic are converging at “around 5% or so.” Full-year organic guidance was raised to 4–5% from 3–4%. The prior report’s bull-case falsifier — “FY2026 organic relapses below ~2%” — has not been hit; the opposite happened. On the top line, CHD is the best performer in large-cap staples this quarter.

2. And yet earnings went backwards. Adjusted EPS was $0.89 versus $0.94 a year ago; adjusted income from operations fell $28.7M (−9.1%); adjusted operating margin fell ~220bps to ~18.8%. First-half adjusted EPS of $1.84 is below the $1.85 of H1 FY2025. This is the single most important change since the last report and it was not visible in the prior memo, which framed FY2026 as a “show-me reacceleration” without anticipating that the reacceleration would arrive with negative operating leverage.

3. A new acquisition, and a candid mark-down of the last one. Miss Mouth’s Messy Eater closed 2026-05-28 for ~$325M all-in against ~$80M of FY2025 sales — ~4.1x sales, cheaper than Touchland but still a full price. More consequentially, the CEO put Touchland’s growth outlook at “high single digits” — a brand acquired eleven months earlier at ~7.6x sales for ~$870M all-in. The prior report’s bear falsifier of “another richly-priced acquisition” is partially hit (4.1x is not 7.5x), and the Touchland impairment thesis has strengthened without yet crystallising.

4. The buyback stopped and the insider buying stopped. CHD repurchased zero shares in H1 FY2026 (versus $300M in H1 FY2025 and ~$900M across FY2025), while spending $300M on Miss Mouth’s and $158.7M on the Touchland earnout, drawing commercial paper for the first time. Separately, the five-year Form 4 corpus contains ten open-market purchases, all between December 2024 and 2025-08-12 at $91–107 — and none since.

5. The peer premium has largely closed — a correction to the prior report. On same-date TTM data to 2026-06-30, Colgate trades at 21.2x EV/EBITDA, above CHD’s ~19.3x; P&G is 16.0x and Clorox 15.1x. The prior memo’s claim that CHD carried a premium to Colgate (~16x) and P&G (~15x) no longer holds on current numbers. CHD is mid-pack, not the outlier. This genuinely weakens one leg of the bear case, and it is why the fair-value zone in Claude’s Take moves up rather than down despite a worse operating quarter.

The net: the prior report’s central swing variable — organic durability — resolved favourably. A different variable, unflagged last time, resolved unfavourably: the conversion of that growth into profit. The call does not change; the reason for it does.

1. Executive Summary

Church & Dwight is a ~$6.2B-revenue, US-centric consumer-staples company built on a portfolio of #1/#2 brands in narrow household and personal-care niches — Arm & Hammer, OxiClean, Batiste, Waterpik, TheraBreath, Hero and Touchland, seven “power brands” that account for roughly 70% of net sales and profits — plus a small, stable Specialty Products division that is the largest US producer of sodium bicarbonate. The model is capital-light: ~5,550 employees, capex of ~2% of sales, ~$823M of net PP&E on ~$6.2B of revenue, and cash from operations guided to ~$1.175B in FY2026.

The operating news is genuinely good at the top line. Second-quarter organic sales grew 5.8% — the second consecutive quarter of industry-leading growth, and this one without the inventory-comparison asterisk that qualified Q1’s +5%. It was volume-led (+4.3%) with positive price/mix (+1.5%) and broad-based: Domestic +5.1%, International +9.1%, Specialty Products +2.8%. Underneath, TheraBreath took 4.5 share points to reach 25.3% of mouthwash and is now #2 in the category; Arm & Hammer cat litter grew consumption 7.5% and added 0.8 points of share; global e-commerce grew 22.7% and is now 25.5% of consumer sales. Management raised full-year organic guidance to 4–5% from 3–4%, raised the cash-flow guide to ~$1.175B, and raised the low end of adjusted-EPS growth.

The earnings news is not good. Despite that growth and 40bps of adjusted gross-margin expansion, adjusted income from operations fell $28.7M, or 9.1%, and adjusted EPS fell to $0.89 from $0.94. The adjusted effective tax rate dropped from 23.8% to 20.3%; at the prior year’s rate the quarter would have earned roughly $0.85 and missed its own $0.88 outlook. First-half adjusted EPS is down 0.5% year over year on 5.4% organic growth. Two forces explain the gap: a −400bps manufacturing-and-logistics drag inside the gross-margin bridge (labour, commodities, tariffs and a transportation spike), and 220bps of adjusted SG&A deleverage driven by the amortisation and operating costs of the Touchland and Miss Mouth’s acquisitions. Consumer Domestic segment profit, adjusted for $47.2M of prior-year exit costs, fell roughly $41.6M.

The full-year guide is therefore extremely back-half weighted. FY2026 adjusted EPS growth of 6–8% off a $3.53 base implies $3.74–$3.81. With H1 at $1.84 and Q3 guided to ~$0.89, the implied fourth quarter is $1.01–$1.08 against ~$0.87 last year — growth of 16% to 24% in a single quarter, following a first half that was flat to down. Part of that bridge is mechanical and credible (the Touchland cost drag anniversaries after July 2025; the gross-margin bridge steepens to >100bps in H2 on productivity; a lower full-year tax rate of ~21%; ~$15M of Phase II tariff refunds). Part of it is not yet evidenced.

Capital allocation has deteriorated in mix, not in prudence. Zero shares were repurchased in the first half — against $300M in the prior-year half and ~$900M across FY2025 at descending prices of $95.71/$92.81/$83.59 — while $300M went to Miss Mouth’s (~4.1x sales) and $158.7M to settle the Touchland earnout. Net debt rose to ~$2.0B and the company drew commercial paper for the first time. Most tellingly, the January 2026 one-time 2030 Strategy PSU grant — $5.0M at target and $7.5M at maximum for the CEO — is tied to three equally weighted net sales CAGR measures with no return-on-capital gate, at maximum thresholds of 3.0% (Arm & Hammer), 10.0% (international) and 8.0% (oral care). Combined with an annual plan on net sales/gross margin/adjusted EPS/cash flow and regular PSUs on relative TSR, there is no ROIC, ROE or economic-profit metric anywhere in this company’s compensation — at a company whose ROIC has fallen from 16.7% (FY2020) to 13.0% (FY2025) on ~$840M+ of brand write-downs.

Valuation is no longer a peer-premium argument; it is an earnings-trajectory argument. At $101.30 the stock carries a market capitalisation of ~$24.0B and an enterprise value of ~$26.0B, or roughly 19.3x TTM EBITDA and 4.18x TTM sales, versus Colgate at 21.2x, P&G at 16.0x and Clorox at 15.1x on the same date. On its own decade, CHD sits at the 35th percentile on P/B and the 56th on P/S — unremarkable. The tension is that ~26.6–27.1x guided FY2026 adjusted EPS is being paid for a company whose adjusted operating profit is currently shrinking, and whose full-year number depends on a fourth quarter that must grow 16–24%.

2. Business Overview

Church & Dwight, founded in 1846 and headquartered in Ewing, New Jersey, develops, manufactures and markets household and personal-care consumer products plus specialty industrial chemicals. It is run by CEO Richard A. (Rick) Dierker, the former CFO, who took the role on 2025-04-02, and CFO Lee McChesney, appointed March 2025. There is no founding-family control; CHD is a widely held S&P 500 constituent.

Three segments. Consumer Domestic (~76% of Q2 net sales; $1,155.8M in the quarter, +0.1% reported, +5.1% organic) is the core US household and personal-care business: laundry detergent (Arm & Hammer value detergent, OxiClean, Xtra deep-value), cat litter, condoms (Trojan), oral care (TheraBreath, Waterpik, Arm & Hammer toothpaste, Orajel), acne (Hero/Mighty Patch), dry shampoo (Batiste), hand sanitiser (Touchland), stain removal (Miss Mouth’s, new), women’s health (First Response), depilatories (Nair) and cold care (Zicam). Consumer International (~19%; $297.5M, +7.2% reported, +9.1% organic) sells the power brands across Canada, Europe, Mexico, Australia and 100+ export markets through the Global Markets Group, and includes Sterimar nasal care. Specialty Products (~5%; $76.7M, +2.8%) is the largest US producer of sodium bicarbonate — made from Wyoming trona through a Tata Chemicals partnership — plus animal-nutrition supplements and specialty cleaning.

The portfolio is bought, not built, and it keeps being bought. Six of the seven power brands were acquired since 2001. Since the prior report the company added an eighth branded asset, Miss Mouth’s Messy Eater, on 2026-05-28. Management describes the acquisition machine as a core competency and, on the Q2 call, explicitly as an accelerating one: the international M&A function was restructured “about 6 to 8 months ago” from a centre-of-excellence model to one where country management teams own deal sourcing, after which, in Dierker’s words, “we went into like right from first to third gear,” having “filtered through 100 deals over the last 6 to 12 months.”

Business model and revenue quality. Revenue is habitual, low-ticket, repeat-purchase consumption sold through mass retail, club, drug, dollar, pet and — increasingly — e-commerce. Online is now 25.5% of total consumer sales, growing 22.7%, among the highest digital mixes in staples. Manufacturing is deliberately asset-light with meaningful contract-manufacturing use; only the strategic sodium-bicarbonate vertical is owned outright. Marketing runs at or above 11% of sales and is the true competitive investment; R&D is modest at ~2.3% of sales and sits inside SG&A.

What has changed structurally. The 2025 portfolio actions — exiting the vitamins (VMS), Flawless, Spinbrush and Waterpik showerheads businesses — are now fully lapped in the organic figures but still depress reported revenue, which is why net sales grew only 1.6% against 5.8% organic. Management’s full-year reported-sales guide of flat to +1% (raised from −1.5% to −0.5%) makes the same point: the company is growing well underneath a shrinking reported base. That is a genuine improvement in portfolio quality; it also means reported revenue and organic revenue tell materially different stories, and anyone reading the headline top line will understate the business.

Verdict. A high-quality, defensive, capital-light branded-consumer business with real #1/#2 positions in habitual niches, an unusually strong digital channel, and a portfolio that is meaningfully cleaner than it was eighteen months ago. The offsetting structural feature is unchanged and central: this is an acquisition-dependent franchise whose growth engine requires continuous capital deployment into brands purchased at high multiples of sales, and the company has now added two more of them.

3. Industry Dynamics

CHD competes in US and global household & personal care (HPC) — a mature, consolidated, low-growth oligopoly that pays dominant brands high returns on capital while offering little structural volume growth. Nothing about that has changed since the last report. Two things about the current cycle have.

Category growth is running slightly better than planned, and management is not extrapolating it. CHD’s largest categories grew ~2.7% in consumption in Q2 against an internal assumption of ~2%; Dierker kept ~2% as the go-forward planning number, calling it “a good in general, walking around number for a while.” That is the right posture, and it is consistent with the peer set: P&G’s most recent quarter produced ~1% organic growth with flat volume, Colgate is running 1–4% organic, and Clorox is at 2–3% on a flat reported top line. CHD’s +5.8% is therefore share gain, not category lift — an important distinction, because share gain is a harder thing to annualise than a rising tide.

The promotional environment intensified when theory said it should abate — and the reason is fiscal, not competitive. Historically, when input costs spike, promotional intensity falls because manufacturers protect margin. That did not happen this quarter. In laundry, category promotional spend rose ~200bps, Henkel’s rose ~1,100bps and P&G’s ~200bps, while CHD’s fell ~300bps. Dierker’s explanation is worth quoting because it is both plausible and self-implicating: “I believe that a lot of tariff rebates are happening from retailers and to other manufacturers, and they’re competing that away a bit.” CHD is doing precisely the same thing — it expects ~$15M of Phase II tariff refunds in H2 2026 and has said it “will invest these proceeds in consumer-facing activities.” (Fact: the refund and the reinvestment commitment. Interpretation: that competitor behaviour is refund-funded — this is management’s hypothesis about rivals, unverified.) The read-through is that a one-time fiscal windfall is being recycled into the promotional pool industry-wide, which suppresses the whole category’s margin conversion in 2026 and creates a hard comparison in 2027 when it stops.

Input costs are worse than the “transitory $30M” framing suggests. Management sizes the Middle East conflict headwind at ~$30M for FY2026 on an assumed crude price of ~$90/barrel — a lower oil assumption than the prior report’s $95–100/barrel, with the same dollar headwind. But the segment disclosures show far larger gross pressure: Consumer Domestic alone absorbed $56.4M in Q2 and $85.7M in H1 of “inflation, including Middle East conflict-related commodity and transportation costs,” and the consolidated adjusted gross-margin bridge shows −400bps of manufacturing and logistics drag in the quarter (labour, commodities, tariffs, transportation) offset by +180bps volume/mix, +150bps productivity and +110bps acquisition/portfolio mix. The $30M is the incremental Middle-East slice, not the total burden. Investors anchoring on $30M are anchoring on roughly a third of the actual gross headwind.

Pricing remains off the table, by choice. Asked directly by three analysts why the industry is not pricing against a clear cost justification, Dierker was consistent: “consumers are pressed… when you see stuff go on promotion, I would say elasticities are higher than they normally would be.” The company is absorbing cost through productivity and trade optimisation, and will consider pricing only “if this inflationary environment stays higher for longer.” (Interpretation: for a portfolio where roughly a third of consumer revenue is value-tier, this is the correct commercial call and simultaneously the structural constraint — CHD has less pricing latitude than Colgate or P&G precisely because its franchise is built on being the value answer.)

Private label remains the defining structural threat and it is where CHD is most exposed. US private label continues to grow faster than national brands, and penetration is highest in exactly CHD’s value categories — value laundry and cat litter. The company’s barbell is a partial defence: Arm & Hammer is the branded value option. But the evidence this quarter is that the defence costs something. Arm & Hammer laundry consumption grew only ~1%, in line with the category, and share was maintained rather than gained — a first in a franchise management describes as having gained share “year after year” for 15–20 years.

Capital-cycle read (Marathon lens). The HPC core remains the favourable capital-cycle case: brand and scale barriers keep new supply out, so high industry returns persist because capital cannot easily enter to compete them away. The cautionary signal is not on the supply side of the industry but inside CHD’s own capital cycle. Marathon’s asset-growth anomaly says that companies growing their asset base fastest tend to earn the worst subsequent returns; CHD has added roughly $1.2B of acquired intangibles and goodwill across Touchland and Miss Mouth’s in thirteen months while its return on invested capital sits four points below its 2020 level. That is the shape the anomaly describes.

Verdict. Structurally attractive but low-ceiling, and currently margin-hostile. The industry remains defensive, supply-disciplined and high-return, but ~2% category growth, a tariff-refund-funded promotional war that punishes non-promoters and promoters alike, record private-label penetration concentrated in CHD’s value tier, and a cost environment whose gross burden is roughly three times the headline “transitory” number make 2026 an unusually poor year for converting revenue growth into profit growth. CHD is winning the volume battle in a market where volume is currently expensive to win.

4. Competitive Position

CHD’s moat is a portfolio of narrow, category-local franchises: brand/intangible captivity plus category-specific scale, with a distinctive low-cost value-tier overlay. There is no enterprise-wide scale advantage — CHD is roughly one-fourteenth of P&G and one-third of Colgate — and the strategy is explicitly to avoid head-on competition and own niches. This quarter provided unusually clean evidence on both the strength and the limits of that moat.

Naming the moat by source (Greenwald taxonomy).

Customer captivity / brand — real, category-local, and demonstrably compounding in oral care and litter. The strongest evidence in the quarter came from TheraBreath, which grew consumption over 20% and took 4.5 share points to reach 25.3% of total mouthwash, consolidating the #2 position “less than 1,000 basis points from the market leader,” Listerine. Household penetration is only 14% against a 65% category, which is the definition of runway rather than saturation. The brand is now extending into toothpaste and has already reached ~1 share point of total toothpaste having only fully entered brick-and-mortar in recent months — and Dierker was refreshingly honest about why the extension worked: “we never deserved the space that we got for THERABREATH toothpaste. But because of the success of the mouthwash, we got some premium great shelf space.” (Interpretation: that sentence is a precise description of a brand-derived distribution advantage — captivity in one category converting into shelf in an adjacent one. It is the single best piece of moat evidence in this report.) Arm & Hammer cat litter is the other clean case: consumption +7.5%, share +0.8 points to 24.5%, driven by the Dual Defense with Microban launch, achieved “within historical levels” of promotion while competitors “are spending a lot.”

The value-tier as a counter-cyclical moat — tested this quarter, and it held, but only just. Roughly a third of consumer revenue is value brands. The test was severe: Henkel raised laundry promotional spend ~1,100bps and P&G ~200bps while CHD cut its own ~300bps. CHD held share with consumption growth of ~1% against category growth of ~1%. Holding share while withdrawing promotion against that kind of competitive step-up is genuine pricing power and validates the “intersection of value and quality” positioning. But the honest reading is that this is a moat defending, not advancing — in the company’s single largest category, the outcome of the quarter was parity.

Category-specific scale — intact. CHD’s advantage is being the dominant brand with the deepest shelf and most efficient advertising within a narrow category (litter, condoms, baking soda) that a P&G-sized rival has little incentive to attack and a small entrant cannot match. Add to this an operational capability that is genuinely differentiating and easy to overlook: a single North American ERP system that allowed Miss Mouth’s, closed on 2026-05-28, to be “fully integrated by end of August” — roughly three months. For a serial acquirer of small brands, integration speed is a real source of acquisition advantage and partially justifies paying above-market multiples, because CHD can scale a brand faster than the seller or a rival bidder could.

Pressure-testing — three cracks, one new.

(1) ROIC remains the honest scorecard, and it has not recovered. Return on invested capital was 16.74% in FY2020, 15.76% in FY2021, and 12.99% in FY2025. Return on equity is healthier at 17.62% in FY2025 (note: this corrects the prior report’s ROE series, which showed 10.8% and does not reconcile — FY2025 net income of $736.8M against ~$4.0–4.2B of average common equity is ~17–18%). A ~13% ROIC still clears the cost of capital and remains a real, if narrowed, advantage. But it is four points below where this franchise operated when it earned its reputation, and nothing in this quarter moved it.

(2) Batiste has reversed — the first power-brand share loss of the cycle, and it is new since the prior report. In the US, Batiste grew consumption ~2% against category consumption of +5.5% and lost ~1.4 share points. Management was candid that “that was closer to 4 or 5 share points in prior quarters” — i.e. a swing from taking four-to-five points to losing one-and-a-half. Dierker attributes it to sizes, offerings and price-pack architecture, with remedies “already in market or lined up for market in late this year, early next year,” and notes Batiste internationally is “growing double digits.” (Interpretation: a genuine, quantified crack in a designated power brand. It is fixable and management has diagnosed it specifically, which is more than can be said of most share losses — but it belongs on the watch list, because dry shampoo is exactly the kind of premium-discretionary niche where a value-positioned parent has the least natural advantage.)

(3) Waterpik is still a power brand on paper and a declining business in the footnotes. The 10-Q describes the global Waterpik business as “experiencing customer distribution losses and a decline in consumer demand, mainly due to lower consumer spending and more customers choosing value brands amid inflation,” which “has reduced sales, profits, and expected cash flows, eroding much of the excess fair value over carrying value.” The trade name carries at $644.7M — 38.6% of the entire $1,672.2M indefinite-lived trade-name balance — with fair value at only 117% of carrying value at the October 2025 test, down from 135% a year earlier. The valuation rests on an 8.0% discount rate, EBITA margins around 25%, and “projected mid-single- to low double-digit revenue growth” for a business the same document describes as declining. (Interpretation: that assumption set is the gap. A declining business modelled at mid-single to low-double-digit growth with only 17% headroom is a charge waiting for a trigger, and the next annual test is in Q4 2026. The company has also ceased importing “substantially all Waterpik flossers” from China into the US, which addresses tariff cost but is itself a disruption to the supply chain of the asset in question.)

Direct peer contrast. CHD’s ~13% ROIC remains well below Colgate’s and P&G’s 30%-plus and below Kimberly-Clark’s high-teens, roughly in line with Clorox. Its ~45% gross margin sits below Colgate (~60%) and P&G (~51%) but above Kimberly-Clark. On growth, however, the comparison has inverted since the prior report: CHD’s 5.8% organic is roughly five times P&G’s ~1%, comfortably ahead of Colgate’s 1–4% band, and double Clorox’s 2–3%. For the first time in this cycle, CHD’s growth premium is real and visible. It simply is not reaching the earnings line.

Verdict. A genuine, narrow, and currently well-executed competitive position — with real and compounding captivity in oral care, litter and acne, a value-tier franchise that just proved it can hold share without buying it, and a structural integration advantage in the ERP. The moat is not eroding; if anything the brand-level evidence this quarter is the best in two years. What has not improved is the financial expression of that moat: ROIC is stuck at ~13%, one power brand has begun losing share, and another is carried at a valuation its own footnote struggles to support. A moat you cannot see in returns on capital is a moat that is being competed away somewhere else — here, in the price paid to acquire it.

5. Growth History and Forward Opportunities

History. Organic growth ran ~+4.3% (FY2021), ~+1.4% (FY2022, the inflation volume air-pocket), ~+5.3% (FY2023), ~+4.6% (FY2024) — then collapsed to ~0.7% in FY2025, with roughly flat volume and slightly negative price/mix. FY2025 missed every leg of the company’s “Evergreen Model” (≈3–4% organic, ~8% adjusted EPS growth, annual margin expansion), with adjusted EPS growing just 2.6% and gross margin down ~100bps.

FY2026 to date: a genuine, two-quarter reacceleration.

Q1’s +5% carried roughly two points of year-ago inventory-comparison tailwind, which the prior report properly discounted. Q2 carries no such asterisk — management stated consumption and organic are both running “around 5% or so,” and independently reported that categories grew 2.7%, so the gap between the two is share gain. Full-year organic guidance was raised a full point to 4–5%.

Where the growth is coming from, and how durable each source is.

Oral care behind TheraBreath — the highest-quality growth in the portfolio. Consumption +20%-plus, 4.5 points of share to 25.3%, #2 in mouthwash, and a toothpaste extension already at ~1 share point with distribution still filling in. Household penetration of 14% against a 65% category means the runway is penetration, not share-of-existing-user — the most durable growth there is. Management flagged capacity investment for TheraBreath inside the FY2026 capex plan, which is corroborating evidence that the demand is real.

International — the fastest and most credible segment. +9.1% organic, broad-based across Europe, Asia and Latin America, driven by taking TheraBreath, Hero and Batiste into markets where CHD already has distribution. Dierker: “we are still in early innings… for THERABREATH and HERO and very early for TOUCHLAND,” hitting “#1 share positions in many, many countries.” The mechanism here is unusually good: CHD buys a US premium brand, then scales it through an existing international infrastructure — that is genuine synergy, not financial engineering, and it is the strongest argument for the acquisition strategy.

Innovation and distribution. New products are framed as roughly half of organic growth. Q1’s total-distribution-points growth was ~11–12% against an industry average of 5–6%, and Dierker noted the benefit “takes a while to reset,” implying a carry-over tailwind into 2027. Named launches: TheraBreath toothpaste and Complete rinse, Arm & Hammer Dual Defense with Microban litter, Hero cleansers and Mighty Shield liquid patch.

Acquired growth. Miss Mouth’s is the newest leg. The metrics management cited are strong — consumption +50%, ~3.5 share points gained, 13% share at one major retailer within months, household penetration of only 2.5% against a 50% category, ACV of 35% against 80%. The distribution runway is real and CHD’s ERP lets it be captured fast.

The skeptical read on the forward algorithm. Three qualifications.

First, the H2 organic guide implies deceleration, not continuation. Q3 is guided to ~3% against ~5.4% delivered in H1. Management’s defence is a two-year stack (5% in H1, 6% in H2), which is a fair framing, but the guided single-year number is a meaningful step down and the full-year 4–5% therefore rests on Q4.

Second, Touchland has decelerated sharply. Bought at ~7.6x sales in July 2025 on triple-digit growth, its outlook is now “probably high single digits these days.” Management’s optimism rests on back-half innovation, brand collaborations, activations and 2027 international expansion — i.e. on things that have not happened yet. A single-product hand-sanitiser brand growing high-single-digits is a perfectly good business; it is not the business that justified 7.6x sales.

Third, Batiste US is going backwards in a category growing 5.5%, which is the first evidence in this cycle that CHD can lose a niche it owns.

Verdict. Higher-quality growth than at the last report, and the best in the peer set — but not yet self-funding. Two clean organic quarters, penetration-led runway in oral care, and a genuinely differentiated international scaling machine are real improvements over the FY2025 stall. Against that: the guide decelerates in H2, the most expensive recent acquisition has decelerated to high-single-digits, one power brand is losing share, and — the theme of this report — none of the growth reached the earnings line in the first half. Growth is necessary and CHD now has it. On current evidence it is not sufficient.

6. Financial Quality

CHD’s financials remain high-quality on cash generation and the balance sheet, and the blemish has shifted. In the prior report the blemish was returns on capital and impairment-driven GAAP volatility. Both persist. A new one has been added: operating leverage has gone negative.

Margins and returns.

(Source: a third-party data provider, reconciled to filings. The 2022 and 2024 troughs in EBITDA margin, ROIC and ROE are impairment artifacts — Flawless/Waterpik in 2022, the $369M VMS charge in 2024 — not operating deterioration. The trend that matters is the top-to-bottom comparison: ROIC 16.7% → 13.0%, ROE 27.6% → 17.6% across five years.)

The central quality issue this quarter: growth without profit.

The mechanism is fully disclosed and worth stating precisely. The adjusted gross-margin bridge is +180bps volume/mix, +150bps productivity, +110bps acquisition-and-portfolio mix, against −400bps of manufacturing and logistics cost (labour, commodities, tariffs, transportation) — netting to +40bps. Below the gross line, adjusted SG&A deleveraged 220bps on Touchland and Miss Mouth’s amortisation and operating costs, and marketing rose $8.2M. The result is an adjusted operating profit that fell 9.1% on 5.8% organic growth.

Quality-of-earnings flags — four, two of them new.

(1) The Q2 “beat” was a tax beat. NEW. The adjusted effective tax rate fell to 20.3% from 23.8% “as a result of continued tax planning initiatives.” Holding the prior-year rate constant, adjusted EPS would have been approximately $0.85 — a ~9.5% decline and a miss against the company’s own $0.88 outlook. (Interpretation: tax planning is a legitimate and repeatable source of value, and a ~21% full-year rate is guided rather than opportunistic. But a beat delivered below the operating line should not be read as operating momentum, and the gap between “+5.8% organic, beat the quarter” and “adjusted operating profit −9.1%” is the whole quarter.)

(2) The full-year guide is back-half-loaded to an unusual degree. NEW. This is the most important derived number in this report.

(Method: FY2025 adjusted EPS of $3.53 less reported Q1 $0.91 and Q2 $0.94; Q3 FY2025 of ~$0.809 is derived from management’s statement that the ~$0.89 Q3 FY2026 guide represents “approximately 10% growth versus last year”; the Q4 FY2025 residual is ~$0.87. FY2026 guidance of +6–8% gives $3.74–$3.81; deducting H1 actual and the Q3 guide leaves the implied Q4.)

So the company raised full-year guidance on a first half in which adjusted EPS declined, and the raise is carried entirely by a fourth quarter that must grow 16–24% year over year. Part of this bridge is mechanically credible: Touchland closed on 2025-07-16, so its ~220bps of SG&A and amortisation drag begins anniversarying from Q3 and is fully lapped in Q4; the CFO stated the gross-margin guide “implies that gross margin will expand over 100 basis points in the back half”; the full-year tax rate steps to ~21%; ~$15M of Phase II tariff refunds land in H2; and Q2’s transportation spike was described as containing “some anomalies.” Part of it is not evidenced: a 16–24% quarter requires all of the above to land simultaneously with no further cost surprise, and management has already conceded that Q2’s own gross margin came in below its internal expectation. (Interpretation, labelled: I would treat the low end as achievable and the high end as aspirational. The risk is not a catastrophic miss; it is a $3.65-ish outcome that turns a “raise” into a trim.)

(3) The cash-flow improvement is more working capital than earnings. Reported H1 cash from operations rose 10.8% to $461.6M. But the pre-working-capital subtotal was $596.6M against $602.6M — slightly down — and the prior-year figure included $51.0M of non-cash business-exit impairment add-backs. Adjusting for those, underlying pre-working-capital operating cash rose roughly 8%, which is genuinely good; the reported +10.8% is additionally flattered by a smaller working-capital build (−$135.0M versus −$186.1M). Two sub-items: non-cash compensation rose to $42.6M from $30.2M, largely the $12.6M Touchland founder restricted-stock charge; and inventories built $65.4M in H1 against $2.9M a year earlier, taking the balance to $601.9M from $534.8M. Management’s statement that consumption and organic are both ~5% argues the build supports real demand rather than channel loading, but it is a watch item for Q3.

(4) GAAP earnings remain distorted, and negative tangible book persists. Reported diluted EPS of $0.85 in Q2 (+9.0%) and $1.76 in H1 (+6.0%) both flatter the trend because the prior-year periods carried business-exit charges. Full-year reported EPS is guided +20–22% against adjusted +6–8% for the same reason. Goodwill and intangibles of roughly $6.1B exceed total equity of $4.35B, so tangible book value is negative — normal for a serial brand acquirer, and precisely why the impairment record and the Waterpik headroom matter: equity is the residual after marks on acquired brands.

Cash flow and the balance sheet — still the strong points. FY2026 cash from operations is guided to ~$1.175B (raised from ~$1.150B) against capex of ~$130M (~2% of sales), implying roughly $1.045B of free cash flow, comfortably covering the ~$292M dividend. The cash-conversion cycle remains tight at roughly three weeks. On the balance sheet at 2026-06-30: cash $254.8M (down from $409.0M at year-end), short-term borrowings $49.9M (the first commercial paper drawn — previously zero), long-term debt $2,206.3M, net debt ~$2.0B against ~$1.80B at year-end, or roughly 1.5x EBITDA. A $2.0B revolver runs to July 2030 and backstops a $2.0B commercial paper programme, with ~$1,943M available. Leverage is conservative and there is ample capacity — which is itself part of the problem, since capacity is what funds the next deal.

Verdict. High-quality on cash and balance sheet; deteriorating on operating leverage; unchanged and mediocre on returns on capital. The business converts revenue to cash as well as it ever did, and the balance sheet is a genuine strength. But a quarter in which the best organic growth in the sector produced a 9.1% decline in adjusted operating profit is not a quarter that demonstrates economics improving with scale — it demonstrates the opposite, and the full-year guide now depends on a fourth quarter doing in three months what the first six could not.

7. Capital Allocation

Capital allocation was the central negative in the prior report and it remains the central negative here — but the specific charge has sharpened. The prior report faulted the prices paid. This report faults the prices paid, the shift away from buybacks, and — the new finding — an incentive structure that contains no measure of return on the capital being deployed.

Capital deployment, five years plus the current half.

The buyback stopped, and the price context matters. CHD repurchased zero shares under its programmes in Q2 FY2026 and zero in H1 FY2026 — against $300M in H1 FY2025 and roughly $900M across FY2025, executed in tranches at descending average prices of $95.71 → $92.81 → $83.59 and retiring ~9.9M shares. The authorisation is unchanged at $228.9M remaining. Instead, the first half’s discretionary cash went to $300.0M for Miss Mouth’s and $180.5M of business-acquisition-liability payments (principally the $158.7M Touchland earnout settled in April 2026), with net debt rising ~$205M and commercial paper drawn for the first time. Shares outstanding rose to 237.14M from 236.55M at year-end as option exercises went unabsorbed.

(Interpretation: buying $900M of stock at an average in the high-$80s and then buying none at $93–103 is defensible capital discipline — arguably it is exactly the price-aware behaviour you want. But it must be read for what it says. Management’s revealed reservation price is somewhere below the current quote. This is the single cleanest valuation signal in the report, and it is management’s own.)

The insider tape says the same thing, and is easy to misread. The five-year Form 4 corpus (1,044 filings, parsed on the structured aff10b5One element rather than a text search) contains exactly ten open-market purchases (code P), all clustered between 2024-12-16 and 2025-08-12 at prices of $91–107: CEO Dierker bought ~$1.75M across 2025-05-13/14 and 2025-08-12 at $92.80–$94.78 and $91.57; CFO McChesney bought ~$494K at $91.38 on 2025-08-08; EVP International Read bought on four occasions. There have been no open-market purchases since 2025-08-12 — twelve months of silence while the stock rose from $91.57 to $101.30.

Against that, 2026 year-to-date insider sales total ~$8.48M across nine filings, none flagged as 10b5-1. That figure should not be read as a bearish signal, and this report will not present it as one: every one of those nine filings also contains a code-M option exercise, and most show zero residual direct holdings — the signature of mechanical exercise-and-sell near expiry, not discretionary conviction selling. The 2025 full-year comparable was ~$12.4M, so the pace is unremarkable. The signal is the absence of buying, not the presence of selling — and it aligns precisely with the corporate buyback halt at the same price band.

M&A — the record, updated.

Touchland’s full cost is now known and larger than the prior report captured: $656.0M net of cash at closing, plus a contingent earnout initially fair-valued at $140.0M and written up to $158.7M (an $18.7M charge) then paid in cash in April 2026, plus $50.0M of founder restricted stock vesting over two years ($12.6M expensed in H1 2026 alone), plus $5.0M of deferred indemnity — ~$870M all-in for a brand with ~$115M of 2024 sales. Both the trade name and the customer relationships carry 20-year useful lives, so they amortise through the P&L, which is the direct cause of the 220bps of adjusted SG&A deleverage this quarter. The goodwill and intangibles are not deductible for US tax purposes.

Miss Mouth’s, at ~$325M all-in against ~$80M of FY2025 sales, is a materially better-priced deal at ~4.1x — and, unlike Touchland, its goodwill and trade name are tax-deductible, a real economic difference worth several tens of millions in present value. The trade name also carries a 20-year life. The commercial case is the strongest of any recent CHD deal on the disclosed metrics: household penetration of 2.5% against a 50% category, ACV of 35% against 80%, consumption +50%, and a three-month integration on CHD’s North American ERP.

(Interpretation: the direction of travel on price is favourable — 7.6x to 4.1x is real discipline, and Miss Mouth’s has a credible distribution-arbitrage thesis that CHD is unusually well-equipped to execute. What has not changed is the pattern: the growth algorithm requires a continuous stream of these, and the largest recent one has decelerated to high-single-digit growth within a year of purchase while carrying an amortising 20-year intangible.)

The incentive structure — the new and most serious finding. CHD’s 2026 DEF 14A discloses three compensation vehicles, and none of them contains a return-on-capital measure:

• Annual Incentive Plan (2026 design): four equally weighted metrics — Net Sales, Gross Margin, Adjusted Diluted EPS, Cash from Operations — with a 25% floor and 200% cap. The Strategic Initiatives metric was removed for 2026.
• Regular Long-Term Incentive: 75% stock options, 15% PSUs, 10% RSUs. The PSU metric is 100% relative TSR.
• One-time 2030 Long Term Strategy Grant (granted January 2026; Dierker’s in March 2026): PSUs cliff-vesting after a four-year performance period running 2026-01-01 to 2029-12-31, forfeited entirely on departure, tied to three equally weighted measures — all of them net sales CAGR.

Three observations. First, the metrics are net sales CAGR with no organic qualifier, and the international leg is defined by geography — “net sales CAGR derived from sources outside of the United States” — rather than by organic contribution. On the plain text, acquired international revenue counts. That matters because doubling international “partly via M&A” is the stated strategy, and because Dierker used the Q2 call to describe an international deal engine that has moved “from first to third gear” after screening 100 targets. The CEO has a $5–7.5M personal award that can be advanced by buying international revenue, and no offsetting metric that penalises overpaying for it. (This is an Open Question rather than a settled fact: the proxy does not state whether acquisitions are included or excluded, and the answer materially changes the severity. It is the first question to put to management.)

Second, the thresholds are not demanding. The Committee describes the goals as “rigorous,” with maximum levels “set far above the maximum levels of the existing incentive plan.” A 3.0% four-year net-sales CAGR for the maximum payout on Arm & Hammer — against a category management itself plans at ~2% — is difficult to reconcile with that description. The International target of 9.5% is essentially the existing Evergreen high-single-digit algorithm, and the division printed +9.1% in the quarter just reported. Oral care at 8.0% maximum sits against a TheraBreath franchise currently compounding consumption above 20%.

Third, and most important: across the annual plan, the regular LTI and this special grant, there is no ROIC, ROE, economic-profit or return-on-capital gate of any kind. The company’s documented failure mode is overpaying for acquired brands — roughly $840M-plus of write-downs across 2022, 2024 and 2025, a near-total capital loss on VMS, and a Waterpik trade name now carrying only 17% of headroom. Its ROIC has fallen from 16.7% to 13.0% over five years. And its newest, largest long-term award pays 0–150% on a measure that acquisitions mechanically increase. (Interpretation: this is not an allegation of bad faith — the plan is broad-based, four-year, service-conditioned and clawback-covered, and the strategic goals themselves are the right ones. It is an observation that the scoreboard measures the numerator and ignores the denominator, at a company whose problem has been the denominator.)

Capital returns to shareholders — disciplined and unchanged. The dividend was raised 4.2% to $0.3075 per quarter in January 2026, extending an unbroken payment record since 1901 and roughly 29 consecutive annual increases. H1 dividends were $145.8M; the full-year run-rate of ~$292M is roughly 28% of guided free cash flow. The yield is ~1.2% at $101.30. This part of the capital-allocation story remains excellent.

Verdict. Prudent on leverage and dividends; improving on acquisition price; and structurally misaligned on incentives. Management deserves genuine credit for paying 4.1x rather than 7.6x for its latest brand, for the 2025 housecleaning, and for declining to buy back stock at prices it evidently considers full. But a company that has destroyed material capital through acquisition has just installed a four-year, $7.5M-maximum CEO award measured purely on revenue growth, with no return-on-capital gate anywhere in its compensation architecture, while simultaneously accelerating its international deal pipeline. That is the wrong scoreboard for this specific company’s specific weakness, and it is why the capital-allocation verdict remains negative despite a better-priced deal.

8. Changes and Headwinds — Last Two Years

Leadership (2025). Rick Dierker, previously CFO, became CEO on 2025-04-02, succeeding long-tenured Matthew Farrell. Lee McChesney joined as CFO in March 2025. Both bought stock personally within months of taking their seats, at $91–95. A January 2026 Investor Day set out the three growth pillars — Arm & Hammer expansion, oral care behind TheraBreath, and international — that now underpin the 2030 Strategy Grant.

Portfolio surgery (2025). CHD exited the vitamins (VMS) business, sold for $160M at the end of 2025 against roughly $650M of invested capital and a ~$357M impairment; announced on 2025-05-01 the exits of Flawless, Spinbrush and the Waterpik showerheads line, taking $51.0M of charges in Q2 2025 ($30.4M fixed-asset and inventory, $20.6M intangible) plus a $12.3M charge on the Flawless trade name and Spinbrush customer relationships, and transferring the Spinbrush IP for nominal consideration in December 2025. These actions removed roughly 8% of reported revenue and are the reason reported net sales grow 1.6% while organic grows 5.8%. (Interpretation: a constructive, costly admission of prior misallocation. It is the single best capital-allocation decision of the period and it is why the portfolio quality is genuinely higher today.)

Acquisitions (2025–26). Touchland closed 2025-07-16 at ~$870M all-in (~7.6x sales), with the earnout written up to $158.7M and paid in April 2026. Miss Mouth’s closed 2026-05-28 at ~$325M all-in (~4.1x sales), financed with cash and the first commercial paper the company has drawn.

Tariffs and trade policy (2025–26). The 10-Q discloses that CHD has taken a range of mitigating actions including “shifting production and relocating manufacturing operations, finding alternative sources of supply, selectively increasing prices, adjusting inventories, seeking exemptions… and most notably ceasing the import of substantially all Waterpik flossers and certain other products from China into the U.S.” The company expects ~$15M of Phase II tariff refunds in H2 2026, which it will reinvest in consumer-facing activity rather than drop to earnings.

The Middle East input shock (2026). A ~$30M full-year cost headwind on an assumed ~$90/barrel crude price, against a prior assumption of $95–100 — the oil assumption fell, the dollar headwind did not. The gross burden running through the P&L is far larger: $85.7M of inflation including Middle East commodity and transportation costs in Consumer Domestic alone in H1, and a −400bps manufacturing-and-logistics drag in the Q2 gross-margin bridge.

The FY2025 organic stall and the FY2026 recovery. Organic growth of ~0.7% in FY2025 gave way to +5.0% and +5.8% in the first two quarters of FY2026, with full-year guidance raised to 4–5%. This is the clearest positive change of the period.

The buyback halt and the incentive redesign (2026). Zero repurchases in H1 2026 after ~$900M in FY2025; the one-time 2030 Strategy Grant installed in January 2026 with three net-sales-CAGR metrics; the Strategic Initiatives metric removed from the 2026 annual plan in favour of four purely financial measures.

ERP. A North American ERP went live in April 2026, described by management as an underappreciated capability that enabled the three-month Miss Mouth’s integration, with further ERP spend inside the ~$130M FY2026 capex plan. Management also flagged pulling forward AI investment, funded out of the earnings over-delivery.

Verdict. Net, these changes strengthen the business and weaken the stewardship case simultaneously. The portfolio is cleaner, the growth is faster, the brands are winning share, and the operational plumbing (ERP, international scaling) is demonstrably better than two years ago. Against that: the two largest recent capital decisions were to buy a decelerating brand at 7.6x sales and to stop buying back stock, and the board’s response to a documented capital-allocation problem was to install a large new award measured on revenue. The thesis is strengthened operationally and weakened on capital discipline — which is precisely why the stock is a hold rather than a buy or a sell.

9. Risk Analysis

The three risks that would actually change the thesis are #1, #2 and #4 — and all three resolve or advance within the next two reporting periods.

10. Valuation Discussion

No price target and no recommendation appear in this section; the discussion is confined to embedded expectations and scenarios.

Where the stock trades. At the 2026-08-14 close of $101.30 — up 3.8% from $97.56 at the prior report date — CHD carries a market capitalisation of roughly $24.0B on 237.1M shares. Total debt of $2,256.2M less $254.8M of cash gives net debt of ~$2.0B and an enterprise value of approximately $26.0B. Against derived TTM figures to 2026-06-30 of ~$6,229M of sales and ~$1,347M of EBITDA, that is ~4.18x EV/Sales and ~19.3x EV/EBITDA. On guided FY2026 adjusted EPS of $3.74–$3.81, the forward multiple is 26.6x–27.1x; trailing GAAP P/E is 33.5x, inflated by the impairment history.

The multiple has expanded since the last report. The comparable calculation at the prior report gave ~18.0x EV/EBITDA. Roughly 1.3 turns of EBITDA have been added in nine weeks, driven by the share price rather than by earnings — which have fallen.

The peer cross-section, on the same date. All figures are TTM to 2026-06-30.

This is a correction to the prior report. That memo argued CHD traded at “a premium to Colgate (~16x), P&G (~15x) and Clorox (~11x).” On same-date data the cohort has re-rated and Colgate now trades above CHD. CHD sits mid-pack, at a modest premium to P&G and Clorox and a discount to Colgate — and it is delivering multiples of their organic growth. The “premium multiple for peer-average growth” leg of the prior bear case no longer holds: CHD’s growth is now the best in the group. What survives is the return-on-capital gap, which is unchanged and large — CHD’s ~13% ROIC against 30%-plus at Colgate and P&G.

Against its own history, the stock is unremarkable. The public own-history percentile ranks as of 2026-08-14 place CHD at the 56.7th percentile composite, with P/E at the 78.8th, P/B at the 35.1st and P/S at the 56.3rd. Per the standing caution on serial acquirers with impairment-distorted GAAP earnings, the P/E percentile should be discounted and P/B and P/S read instead. On those, the stock is at or below the middle of its own decade. CHD is not expensive versus its own history. It is expensive versus its own current earnings trajectory.

Embedded expectations — what the price requires. Three things, in order of near-term importance.

(1) The implied Q4 has to land. At $101.30 on $3.74–$3.81 the market is paying 26.6–27.1x a full-year number of which roughly 28% has to be earned in the final quarter at 16–24% growth, after a first half that went backwards. If Q4 lands at, say, $0.95 instead of $1.04, FY2026 adjusted EPS is ~$3.68 and the same 27x multiple gives ~$99 — the stock is roughly where it is, but the “raise” becomes a shortfall and the credibility of the Evergreen algorithm takes damage precisely as the 2027 guide is set.

(2) The Evergreen algorithm has to resume from a back-half-built base. The model calls for ~8% adjusted EPS growth. FY2026 will deliver 6–8% only if the Q4 hockey stick materialises, and that Q4 is flattered by the Touchland cost anniversary and a lower tax rate — neither of which repeats as a growth driver in 2027. The 2027 algorithm therefore has to be carried by operating leverage that has been absent for two quarters. That is the real embedded assumption, and it is not yet evidenced.

(3) The acquired intangibles have to hold their carrying values. $644.7M of Waterpik trade name at 117% of fair value, plus roughly $1.2B of Touchland and Miss Mouth’s goodwill and intangibles added in thirteen months, sit on a balance sheet whose tangible book is already negative.

Scenario frame (illustrative; assumptions stated, not forecasts).

(Assumptions: FY2027 EPS built off FY2026 outcomes of ~$3.81 / ~$3.75 / ~$3.65 respectively, grown at ~9% / ~5% / ~−1%. Multiples anchored to the peer table above and to CHD’s own recent trading range. These are illustrative brackets to frame asymmetry, not forecasts, and no scenario constitutes a target.)

The asymmetry. The upside case requires operating leverage that has been absent for two consecutive quarters and adds roughly 7–15%. The downside case requires only that the Q4 hockey stick disappoints while the multiple converges toward P&G’s 16.0x and Clorox’s 15.1x, and it costs 33–43%. That is an unattractive shape at 27x forward earnings for a business whose adjusted operating profit is currently shrinking. (Interpretation, and the core of the valuation view. The counter-argument, which is real: the sector’s defensive bid has been remarkably durable, CHD’s factor identity is essentially “staples index proxy,” and a cohort re-rating — as just happened at Colgate — can sustain multiples well past what the earnings justify.)

11. Variant Perception

What consensus believes. That FY2025 was an aberration, that the FY2026 organic reacceleration to 4–5% marks CHD’s return to best-in-class staples compounding, that the current cost pressure is transitory and 2027 restores the Evergreen ~8% EPS algorithm, and that the acquisition machine — recently repriced downward from 7.6x to 4.1x — is a durable competitive advantage rather than a capital drain. On the top line, consensus is right and the evidence supports it.

The strongest bull case. CHD is doing something no large-cap staple is currently doing: growing volume. Q2 organic of +5.8% was volume-led (+4.3%) with positive price/mix, against a category growing 2.7% and against P&G at ~1% and Clorox at 2–3%. The share evidence is not soft — TheraBreath +4.5 points to 25.3%, cat litter +0.8 to 24.5%, and Arm & Hammer laundry holding share while reducing promotion against an 1,100bp competitor increase. International compounds at 9.1% by scaling US-acquired premium brands through existing infrastructure, which is real synergy. The penetration runways are enormous and specific: TheraBreath at 14% against a 65% category, Hero at 10% against 30%, Miss Mouth’s at 2.5% against 50%. Free cash flow of ~$1.045B is guided up, the balance sheet is investment-grade at ~1.5x, and the current earnings compression is dominated by two identifiable and lapping items — the Touchland cost drag, which anniversaries after July 2025, and a transportation/commodity spike management has partly labelled anomalous. Get those two behind you and the operating leverage on 5% volume growth in a 45%-gross-margin business is considerable.

The strongest bear case. The best organic quarter in years produced a 9.1% decline in adjusted operating profit and a 5.3% decline in adjusted EPS, and the outlook “beat” was delivered by a 350bp drop in the tax rate — at last year’s rate the quarter missed. Across the first half, 5.4% organic growth produced negative adjusted EPS growth. The company nonetheless raised the full-year guide, which now requires a fourth quarter of +16% to +24%. ROIC sits at 13.0% against 16.7% five years ago and has not responded to two good quarters. The buyback has stopped and no insider has bought a share on the open market since 2025-08-12, both at prices well below today’s. The most expensive recent acquisition has decelerated to high-single-digit growth within a year, a $644.7M trade name is carried at 117% of fair value on growth assumptions its own footnote contradicts, and the board’s response to a five-year record of value-destructive M&A was to grant the CEO a $5–7.5M four-year award measured on net sales CAGR with no return-on-capital gate — while the international deal pipeline shifts into “third gear.” At 27x forward earnings, the price already assumes all of this resolves favourably.

The 3–5 assumptions that actually matter.

1. That the H1 earnings decline is transitional rather than structural. The bull case is entirely dependent on this. Falsified if Q3 adjusted operating income again declines year over year, since the Touchland comparison starts easing in Q3.
2. That the implied Q4 of $1.01–$1.08 lands. Falsified by a Q4 print in the $0.90s or a full-year trim.
3. That the acquired intangible base holds. Falsified by a Waterpik charge at the Q4 2026 annual test.
4. That management does not deploy the balance sheet into another 7x-sales deal. Falsified by any international acquisition above ~5x sales — and the incentive structure now argues for volume of deals rather than restraint.
5. That the value-tier moat continues to hold share without buying it. Falsified if Arm & Hammer laundry share turns negative or if the Batiste US reversal spreads.

The factor-positioning read, and where consensus may be offsides. The the factor model model places CHD as a low-volatility staples proxy: a Consumer Staples sector beta of 0.606 and a LowVolatility beta of 0.412 in the All-Factors model (R² 0.465, in the >30% band), 252-day idiosyncratic volatility of 16.8%, and — most tellingly — nearest factor neighbours that are almost entirely index vehicles: IYK 0.863, RSPS 0.840, KXI 0.824, RHS 0.823, XLP 0.821, VDC 0.802, before the first operating company (General Mills, 0.800). CHD has no distinctive factor identity; it is the staples trade.

That framing matters for the thesis in one specific way. The risk-adjusted record is poor: five-year annualised return 5.1% (Sharpe 0.148), three-year 3.3% (Sharpe 0.063), against a lifetime 14.2% and a maximum drawdown of −31.7%. The last three months returned ~+8.0% (annualised 36.2%, Sharpe 1.47) while the last six months returned approximately zero. (Interpretation, regime-caveated: the multiple has been sustained by the sector’s defensive bid rather than by delivered per-share compounding — three years of ~3% annualised returns is what a de-rating compounder looks like when the sector bid holds the multiple up. This cuts both ways. It means the current 19.3x is not obviously a fundamentals-derived number and could compress quickly if the defensive bid rotates away. It also means it may not compress at all on a single disappointing quarter, because the marginal holder is buying staples exposure, not CHD’s Q4.)

Where I think consensus is offsides. Not on the growth — the growth is real and consensus has it right. Consensus is offsides on the conversion. The market is treating +5.8% organic and a raised guide as evidence of an earnings inflection, when the same quarter’s adjusted operating profit fell 9.1% and the beat came from tax. The muted +1.2% reaction to the print suggests some of the market has noticed; the 1.3-turn multiple expansion since June suggests most of it has not. The second place consensus is offsides is on incentives: a four-year, revenue-only CEO award at a company with a documented overpayment problem is a forward-looking risk that no sell-side model will capture, and it arrives exactly as the international M&A pipeline accelerates.

12. Fact vs. Interpretation

13. Open Questions

1. Do acquisitions count toward the three 2030 Strategy Grant net-sales CAGR metrics? The proxy says “net sales CAGR” with no organic qualifier and defines the international measure by geography. This single answer determines whether the grant is a growth incentive or an acquisition incentive. It is the first question for management.
2. What exactly bridges the implied Q4 of $1.01–$1.08? Management has given the components qualitatively (Touchland anniversary, >100bps of H2 gross margin, ~21% tax, $15M of tariff refunds) but no quantified walk. How much of the 16–24% is the Touchland cost lap, and how much requires new operating leverage?
3. What is Touchland’s actual revenue and profit contribution? CHD does not disclose brand-level revenue. Without it, “high single digits” cannot be tested against the ~$115M 2024 base or against the 20-year amortisation schedule.
4. Will the Waterpik trade name be written down at the Q4 2026 annual test, and what growth rate is now being modelled? The October 2025 test used mid-single to low-double-digit growth for a declining business at 117% headroom.
5. Why no buyback at all in H1 with $228.9M authorised and ~$1.045B of free cash flow? Is this an explicit valuation judgement, or capital being reserved for the international pipeline?
6. What is the international M&A pipeline’s size and price discipline? “100 deals filtered” and “first to third gear” describe activity, not standards. What multiple range is management prepared to pay?
7. Is the $65.4M H1 inventory build demand-driven or channel-driven? Management says consumption ≈ organic ≈ 5%, which argues the former; Q3 will settle it.
8. What is the plan if the promotional environment does not normalise in 2027 when tariff refunds stop? CHD has explicitly deferred pricing in favour of productivity. How much productivity is left?
9. Is Batiste US a price-pack-architecture problem or a brand problem? A swing from +4–5 to −1.4 share points is large for an execution issue.
10. Does the ~$30M “transitory” Middle East framing reconcile with $85.7M of H1 Domestic inflation? The two numbers measure different things but are presented to investors as though the first is the burden.

14. What Must Be True

Bull case — what must be true, and its falsification test.

• The H1 earnings decline is a lapping artifact, not structural deleverage. Two quarters of 5%-plus organic must convert to growing adjusted operating profit once the Touchland cost base anniversaries. Falsifier: Q3 FY2026 adjusted operating income again declines year over year, with the Touchland comparison already easing.
• The implied Q4 lands. Adjusted EPS of $1.01–$1.08 against ~$0.87, delivered on gross margin and operating leverage rather than on tax. Falsifier: a Q4 print in the $0.90s, or any full-year adjusted-EPS trim.
• The acquired intangible base holds and the M&A instinct stays repriced. No Waterpik charge; Touchland stabilises; the next international deal is struck near 4x sales rather than 7x. Falsifier: a Waterpik impairment at the Q4 test, or any acquisition above ~5x sales.
• The value-tier moat keeps holding share without buying it. Falsifier: Arm & Hammer laundry share turns negative, or the Batiste US reversal appears in a second power brand.

Bear case — what must be true, and its falsification test.

• The growth is real but structurally uneconomic at this cost base — CHD can buy volume and share, but not at a margin that grows earnings, so adjusted EPS compounds below the Evergreen 8% and the 27x multiple converges toward P&G’s 16.0x and Clorox’s 15.1x. Falsifier: CHD sustains 4%-plus organic with adjusted operating margin expanding year over year for two consecutive quarters.
• The incentive structure produces another value-destructive deal. A revenue-only, $7.5M-maximum CEO award plus an accelerating international pipeline plus ~$1.9B of undrawn capacity is a combination that has a known outcome at this company. Falsifier: management resumes the buyback at scale, declines deals above its stated criteria for a full year, or the board adds a return-on-capital gate.
• ROIC stays anchored near 13% while the intangible base grows, confirming that the compounding edge has structurally narrowed. Falsifier: FY2026 ROIC prints above ~14% with the enlarged capital base.

The single most important swing variable has changed since the prior report. It is no longer the durability of organic growth — that question has been answered favourably across two quarters. It is now whether that growth converts. Watch three things, all of which resolve by February 2027: the Q3 adjusted operating income line (not the EPS line, which tax can rescue); the Q4 print against the implied $1.01–$1.08; and the Q4 2026 annual indefinite-lived intangible test on the $644.7M Waterpik trade name. A fourth, less scheduled but equally consequential: the price and multiple of the next international acquisition.

15. Source Appendix

See the Source Appendix and the diligence questionnaire below. Primary sources: CHD Form 10-Q for the quarter ended 2026-06-30 (filed 2026-07-31); the 8-K dated 2026-07-31 and its Exhibit 99.1 earnings release; the Q2 FY2026 earnings-call transcript (2026-07-31); the 2026 DEF 14A (filed 2026-03-19); the FY2025 Form 10-K (filed 2026-02-12); the full trailing 60-month SEC filing record including all Forms 3/4/5; third-party aggregated financial, ratio and valuation data reconciled to filings; public price history and own-history valuation percentiles; a public quantitative factor model; and the public filings and earnings releases of P&G, Colgate, Kimberly-Clark, Clorox and Kenvue.

The analysis above contains no buy/sell recommendation and no price target, by design. The only position taken in this document is in the clearly-labeled “Claude’s Take” block at the top, which is the author’s own subjective opinion and is not investment advice.

APPENDIX A — Standard Diligence Questionnaire

Church & Dwight Co., Inc. (NYSE: CHD) — Standard Diligence Questionnaire

Supplemental to the report above. Report date: 2026-08-15. Update to the 2026-06-14 edition. Fact / Interpretation / Assumption labeled where material.

General

What thoughtful questions have other investors asked about this company? The Q2 FY2026 call (2026-07-31) drew eleven analysts and the questions were, with one telling exception, the right ones. Lauren Lieberman (Barclays) asked why gross margin came in below the company’s own expectation despite an unchanged inflation guide — the CFO conceded “slightly higher transportation costs… even a little bit higher than we thought.” Bonnie Herzog (Goldman Sachs) asked the sharpest question of the call: why, if the top-line and gross-margin guides went up a full point, did the high end of adjusted-EPS guidance not move? The answer was explicit spend-back — “we could, in theory, beat earnings and EPS in any 1 year, but we choose to spend more on marketing.” Chris Carey (Wells Fargo) probed the inflation number as “one of the highest… over the past 4 years.” Kevin Grundy (BNP Paribas) pressed on why the industry is not pricing against a clear cost justification. Robert Moskow (TD Cowen) asked for Touchland specifics and extracted the “high single digits” answer. Javier Escalante (Evercore) got the Henkel +1,100bps promotional figure confirmed.

The exception is the important part: not one analyst asked about the shape of the implied fourth quarter. With H1 adjusted EPS down 0.5% and the full-year guide raised to +6–8%, the implied Q4 of $1.01–$1.08 (+16% to +24%) is the single largest assumption in the model, and it went unexamined on the call. Nor did any analyst ask about the January 2026 Strategy Grant’s revenue-only metrics, or about the absence of any buyback in the first half. (Interpretation: the sell-side conversation is anchored on organic growth and share, where CHD is genuinely winning, and is under-covering the conversion of that growth into profit — which is where the thesis actually sits.)

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Interpretation: Below mid-cycle on margin, above mid-cycle on volume — an unusual and specific combination. Adjusted operating margin of ~18.8% in Q2 is roughly 220bps below the prior-year quarter and well below the ~21% the business ran in 2020–21. Gross margin at 45.4% is near the top of the recent range but is being achieved against a −400bps manufacturing-and-logistics drag, i.e. the underlying cost base is at a cyclical high. Volume growth of +4.3% is at a multi-year high. So earnings are cyclically depressed by input and freight costs while revenue is cyclically strong — which is precisely why the bull case (cost normalisation on top of retained volume) and the bear case (the cost base is the new normal) are both coherent.

Driven by the external environment or internal actions? Both, roughly evenly. External: the Middle East commodity and transportation shock (~$30M incremental, but $85.7M of total H1 Domestic inflation), tariffs, and a promotional environment intensified by competitors recycling tariff refunds. Internal: the 2025 portfolio exits (which depress reported revenue by ~8% but improve mix), the Touchland acquisition (which added ~220bps of SG&A deleverage), deliberate marketing spend-back at or above 11% of sales, and productivity programmes contributing +150bps to gross margin in the quarter.

How stable are revenues? Very. The portfolio is low-ticket, habitual, repeat-purchase consumption across laundry, litter, oral care, acne, condoms, dry shampoo and cold care. There is no contractual recurrence, but consumption recurrence is high and the value-tier tilt makes revenue counter-cyclically resilient — the business gains share when consumers trade down. The visible instability is in reported revenue, which grew only 1.6% against 5.8% organic because of the 2025 exits; that distortion fully laps by the end of FY2026.

Outlook for products/services? Positive on the growth brands and mixed on the legacy set. TheraBreath (consumption +20%-plus, share +4.5 points to 25.3%, 14% household penetration against a 65% category) and Hero (10% penetration against 30%, launching into a $650M cleanser category) have genuine penetration runway. Arm & Hammer cat litter is compounding at 7.5% consumption growth. Against that, Arm & Hammer laundry grew ~1%, Batiste US lost 1.4 share points, and Waterpik is described in the 10-Q as suffering “customer distribution losses and a decline in consumer demand.”

How big will this market be — growing, shrinking, domestic or international? US and global household and personal care is a mature ~2% category. Management plans on ~2% and reported 2.7% consumption growth in its own categories in Q2. The growth optionality is geographic and penetration-led rather than category-led: international is ~19% of sales, growing 9.1% organically, and is the stated priority (roughly $1B to $2B, partly via M&A). (Interpretation: CHD’s addressable growth is a share-and-penetration story inside a flat market, not a market-growth story. That is a harder, more execution-dependent kind of growth — and it is currently working.)

Business Quality & Competitive Moat

Is the industry getting more or less competitive? More, in the near term, and for a specific and probably temporary reason. Promotional intensity rose when cost pressure would historically have suppressed it: category promotional spend +200bps, Henkel +1,100bps, P&G +200bps, while CHD cut its own 300bps. Management’s hypothesis — labelled Interpretation, as it concerns competitors — is that tariff refunds are being competed away. CHD is doing the same with its own ~$15M of Phase II refunds. Underneath the promotional cycle, the structural picture is unchanged: a consolidated oligopoly with high entry barriers, facing record private-label penetration concentrated in exactly CHD’s value categories.

How profitable is the business (ROIC, ROE)? FY2025 ROIC 13.0%, ROE 17.6% (third-party aggregated data, reconciled to the filing — this corrects the prior report’s ROE figure of 10.8%, which does not reconcile: FY2025 net income of $736.8M on ~$4.0–4.2B of average common equity is ~17–18%). The five-year trend is the finding: ROIC 16.7% (2020) → 15.8% (2021) → 13.0% (2025), with impairment-driven troughs at 7.9% (2022) and 9.7% (2024). (Interpretation: ~13% still comfortably clears the cost of capital, so this remains a good business. But it is four points below where the franchise earned its compounding reputation, and two strong organic quarters have not moved it, because the incremental capital keeps going into acquired intangibles rather than into the operating base.)

How profitable is the industry — how many competitors, what barriers to entry? Highly profitable and structurally supply-disciplined, which is the favourable Marathon capital-cycle case: brand and shelf barriers keep new capital out, so high returns persist. The relevant competitors differ by category rather than at the corporate level — P&G and Henkel in laundry, Clorox and Nestlé Purina in litter, Listerine (Kenvue) in mouthwash, Colgate in oral care. CHD is roughly one-fourteenth of P&G and one-third of Colgate and survives by owning niches rather than fighting for categories. Barriers to entry at the category level are real (shelf space, advertising scale, brand trust in habitual purchases); barriers at the corporate level are modest.

Can the business be easily understood? Yes — this is among the most transparent business models in the market. The complexity is not in the operations but in the accounting: seven power brands, ~$6.1B of goodwill and intangibles against $4.35B of equity, negative tangible book, a five-year history of impairments, and GAAP earnings that require adjustment to be interpretable. Understanding CHD means understanding its acquired intangible base, not its factories.

Can it be undermined by foreign low-cost labour? Not materially in the core. Manufacturing is largely US-based and asset-light, and CHD is less tariff-exposed than import-heavy peers. The exception is instructive: the company has “ceased the import of substantially all Waterpik flossers and certain other products from China into the U.S.” — Waterpik, a durable-goods device business rather than a consumable, is the one franchise genuinely exposed to global manufacturing cost, and it is also the one carrying impairment risk.

Do brands matter? Decisively, and this quarter produced the cleanest evidence in years. Arm & Hammer laundry held share while reducing promotional spend 300bps against an 1,100bp competitor increase — that is brand-derived pricing power, not merchandising. TheraBreath’s mouthwash success converted directly into premium toothpaste shelf space that the CEO admitted “we never deserved” on the toothpaste product’s own merits. Both are textbook customer-captivity outcomes.

What is the nature of competition? Innovation, distribution points and price-pack architecture — in that order, per management. CHD claimed industry-leading distribution-point growth of ~11–12% against an industry average of 5–6% earlier in the year, with the benefit carrying into 2027. Promotion is the lever CHD explicitly tries not to pull, positioning instead at “the intersection of value and quality.”

Customers’ switching costs? Effectively zero at the consumer level — these are low-ticket, undifferentiated-in-form categories. The moat is habit and brand trust, not lock-in. At the retailer level, switching costs are higher and asymmetric against CHD: Walmart is ~23% of sales and the top four customers ~44%, and retailers hold private label as a disciplining tool.

Financial Condition & Balance Sheet

Assets not fully recognised on the balance sheet? Yes, and materially. Arm & Hammer, a ~180-year-old internally-developed near-genericized trust mark, carries essentially no balance-sheet value — the brand that anchors the largest franchise and is one of the three 2030 Strategy Grant metrics is invisible in book value. The Trojan and OxiClean franchises are similarly under-carried. The North American ERP, which enabled a three-month integration of Miss Mouth’s, is capitalised at cost and understates its real strategic value as an acquisition-integration capability.

Off-balance-sheet liabilities? Nothing unusual disclosed. The visible contingent items are on-balance-sheet and modest: $25.0M of deferred Miss Mouth’s consideration ($15.0M in 2026, $4.0M in Q2-2029, $6.0M in Q2-2031), $5.0M of deferred Touchland indemnity payable three years from the July 2025 closing, and the unvested half of the $50.0M Touchland founder restricted-stock award. The Touchland earnout, initially fair-valued at $140.0M and written up to $158.7M, was settled in cash in April 2026 and is gone.

How conservative is the accounting? Mixed, and the mix is the story. Conservative in structure: both the Touchland and Miss Mouth’s trade names carry 20-year finite useful lives and amortise through the P&L rather than sitting as indefinite-lived assets — that is why SG&A deleveraged 220bps this quarter, and it is a more honest treatment than most serial acquirers apply. The annual goodwill test performed in early Q2 2026 found fair value “substantially exceeded” carrying value for all reporting units. Less conservative in assumption: the Waterpik trade name is carried at $644.7M with fair value at only 117% of carrying value (down from 135%), valued on an 8.0% discount rate and “projected mid-single- to low double-digit revenue growth” for a business the same footnote describes as “experiencing customer distribution losses and a decline in consumer demand.” (Interpretation: that specific assumption is the least conservative item in the accounts and the most likely source of a future charge.) Separately, the company adjusts out Touchland-related restricted-stock expense ($6.3M in the quarter) from adjusted results while it is genuine, recurring, two-year acquisition consideration.

How CapEx-hungry is the business? Barely. FY2026 capex is guided to ~$130M, roughly 2% of sales, against ~$1.175B of guided operating cash flow — and even that includes discrete items (TheraBreath and Sterimar capacity, the ERP project). H1 capex of $61.8M was up $22.8M year over year to support growth. Net PP&E of ~$823M on ~$6.2B of revenue is genuinely capital-light. The capital intensity of this business is in M&A, not capex — $300.0M for Miss Mouth’s plus $180.5M of acquisition-liability payments in a half-year dwarfed the $61.8M spent on plant.

Capital Allocation & Management

How much FCF does the business generate, how does management use it, what is the philosophy? FY2026 guidance implies ~$1.045B of free cash flow (~$1.175B operating cash flow less ~$130M capex). The philosophy in practice has shifted since the prior report. In H1 2026: $300.0M to acquisitions, $180.5M to acquisition liabilities, $145.8M to dividends, $61.8M to capex, and $0.0M to buybacks — funded by $461.6M of operating cash flow, a $154.2M cash drawdown and $49.9M of net commercial paper, the first CP the company has drawn. The comparison is stark: FY2025 deployed ~$900M into repurchases at average prices of $95.71, $92.81 and $83.59; FY2026 has deployed nothing at $93–103. (Interpretation: this is coherent and arguably admirable price discipline — but it reveals management’s own reservation price sits below the current quote, and it means the marginal dollar is now going into acquired brands rather than into the existing one.)

Significant acquisitions recently? Two in thirteen months. Touchland, closed 2025-07-16, ~$870M all-in ($656.0M net cash at closing + $158.7M earnout paid April 2026 + $50.0M founder restricted stock + $5.0M deferred indemnity) against ~$115M of 2024 sales — ~7.6x sales — with goodwill and intangibles not tax-deductible, and a growth outlook now put at “high single digits.” Miss Mouth’s Messy Eater, closed 2026-05-28, ~$325M all-in ($300.0M cash + $25.0M deferred) against ~$80M of FY2025 sales — ~4.1x sales — with goodwill and trade name deductible for US tax purposes, 20-year trade-name life, integrated in roughly three months, and disclosed metrics that are genuinely attractive (consumption +50%, ~3.5 share points gained, 2.5% household penetration against a 50% category, 35% ACV against 80%). (Interpretation: the price discipline improved markedly — 7.6x to 4.1x — and Miss Mouth’s has the best-articulated distribution-arbitrage case of any recent CHD deal. The pattern that has not changed is that the growth algorithm requires a continuous stream of these.)

Buying back shares? Not currently. Zero repurchases under the programmes in Q2 and in H1 FY2026, with $228.9M of authorisation remaining unchanged. Shares outstanding rose to 237.14M from 236.55M at year-end as option exercises went unabsorbed — so the share count is drifting up.

Issuing large amounts of new shares to insiders? No. Share-count creep is modest and driven by ordinary option exercises. The one non-routine issuance is the $50.0M of restricted stock granted to Touchland’s founder, vesting 50% at each of the first and second anniversaries of the July 2025 closing, expensed at $6.3M in the quarter and $12.6M in the half. Non-cash compensation overall rose to $42.6M in H1 from $30.2M.

Compensation policy of directors/management? This is the most consequential finding of the update. Three vehicles, and none of them contains a return-on-capital measure:

• Annual Incentive Plan (2026): four equally weighted metrics — Net Sales, Gross Margin, Adjusted Diluted EPS, Cash from Operations — with a 25% floor and 200% cap. The Strategic Initiatives metric was removed for 2026.
• Regular LTI: 75% stock options, 15% PSUs, 10% RSUs; the PSU metric is 100% relative TSR.
• One-time 2030 Long Term Strategy Grant (January 2026; Dierker’s in March 2026): four-year cliff-vesting PSUs over 2026–2029, forfeited entirely on departure, tied to three equally weighted net sales CAGR measures — Arm & Hammer (baseline 1.1% / target 2.6% / maximum 3.0%), non-US net sales (7.0% / 9.5% / 10.0%) and oral care including TheraBreath (4.2% / 6.6% / 8.0%). CEO opportunity: $0 at baseline, $5.0M at target, $7.5M at maximum.

(Interpretation: the strategic goals themselves are the right three, the four-year service condition and clawback coverage are genuine safeguards, and broad-based participation is defensible. But the Committee characterises the maxima as “set far above the maximum levels of the existing incentive plan,” and a 3.0% four-year net-sales CAGR for maximum payout on Arm & Hammer — against a category management plans at ~2% — is hard to square with that. More importantly, all three metrics are net sales with no organic qualifier, and the international leg is defined by geography rather than by organic contribution, so on the plain text acquired revenue counts. At a company with ~$840M-plus of brand write-downs and ROIC down four points in five years, granting the CEO a $7.5M-maximum four-year award on revenue growth — with no offsetting return-on-capital gate — points the incentive at exactly the behaviour that caused the problem, and it arrives as the international deal pipeline shifts into what the CEO called “third gear.”)

Motivations of management? Mixed evidence, and worth separating carefully. Favourable: both the CEO and CFO bought stock with their own money shortly after taking their seats — Dierker ~$1.75M across May and August 2025 at $91.57–$94.78, McChesney ~$494K at $91.38 in August 2025, with EVP International Read buying four times. All were discretionary, none 10b5-1-planned. The company was simultaneously repurchasing stock at descending prices. That is aligned, value-aware behaviour. Unfavourable: no insider has made an open-market purchase since 2025-08-12, twelve months during which the stock rose to $101.30, and the corporate buyback stopped in the same price band. A necessary corrective: 2026 year-to-date insider sales of ~$8.48M across nine filings look alarming on a screen but are not — every one also contains a code-M option exercise and most show nil residual direct holdings, the signature of mechanical exercise-and-sell near expiry. The 2025 comparable was ~$12.4M. The signal is the absence of buying, not the presence of selling.

Valuation & Market Data

Is the stock an ADR, MLP, or K-1 issuer? No. Church & Dwight is a Delaware corporation listed on the NYSE, issuing an ordinary Form 1099-DIV. No K-1, no ADR structure, no pass-through complexity.

Dividend policy? Excellent and unchanged. The quarterly dividend was raised 4.2% to $0.3075 in January 2026, extending an unbroken payment record since 1901 and roughly 29 consecutive annual increases. H1 payments were $145.8M; the ~$292M annual run-rate is roughly 28% of guided free cash flow and ~39% of GAAP earnings. The yield is ~1.2% at $101.30 — a growth-oriented rather than income-oriented payout, very well covered, with no plausible coverage risk at ~1.5x net leverage.

How profitable is the business? Highly, in absolute terms; mediocre and deteriorating relative to its own history and to its best peers. FY2025: gross margin 44.7%, EBITDA margin 21.4%, GAAP operating margin 17.4%, net margin 11.9%, ROIC 13.0%, ROE 17.6%. The comparison that matters is against Colgate and P&G at 30%-plus ROIC. And the current-quarter direction is negative: adjusted operating margin fell ~220bps to ~18.8% on +5.8% organic growth.

Is net income diverging from cash from operations? Not in a way that signals accrual quality problems, but the reported improvement deserves unpacking. H1 operating cash flow of $461.6M (+10.8%) against H1 net income of $419.1M is a healthy 1.10x conversion. However, the pre-working-capital subtotal was $596.6M versus $602.6M — down slightly — and the prior-year figure included $51.0M of non-cash business-exit impairment add-backs. Adjusting for those, underlying pre-working-capital operating cash rose roughly 8%; the reported +10.8% is additionally flattered by a smaller working-capital build (−$135.0M versus −$186.1M). One watch item: inventories built $65.4M in H1 against $2.9M a year earlier, taking the balance to $601.9M. Management’s statement that consumption and organic are both running ~5% argues this supports real demand rather than channel loading, but Q3 will settle it. (Interpretation: cash quality is good; the headline growth rate in cash flow is better than the underlying earnings-driven growth rate, and readers should use the ~8% figure.)

Risks & Downside

What factors would cause the stock to decline? In descending order of near-term probability: (1) a fourth quarter that misses the implied $1.01–$1.08 and turns a raised guide into a trim — the highest-probability, highest-impact risk, and the least discussed; (2) a Waterpik trade-name impairment at the Q4 2026 annual test, with $644.7M carried at 117% of fair value on growth assumptions the footnote itself contradicts; (3) another richly-priced acquisition, which the new incentive structure makes more rather than less likely; (4) persistence of the input-cost and transportation pressure that produced a −400bps gross-margin drag, against a company that has explicitly declined to price; (5) escalation of the promotional war as tariff refunds are competed away, hitting all participants; (6) multiple convergence toward P&G’s 16.0x and Clorox’s 15.1x from CHD’s ~19.3x; (7) private-label share gains in value laundry and litter, where Arm & Hammer’s laundry consumption grew only ~1%.

Risk of a catastrophic loss? Low. The realistic severe case is a de-rating, not an impairment of the business: a Q4 miss plus a Waterpik charge plus multiple convergence to ~16x on a ~$3.60 earnings base implies roughly $58–68, or a 33–43% decline. That is a genuine and quantifiable downside, and the asymmetry against a ~7–15% bull case is the central valuation objection in this report. But it is a valuation loss, not a solvency or franchise loss.

Chance of a total loss? Negligible. Net debt of ~$2.0B is ~1.5x EBITDA against ~$1.045B of annual free cash flow; all debt is fixed-rate senior notes with a well-termed ladder; ~$1,943M of revolver and commercial-paper capacity is available under a facility running to July 2030; the portfolio spans seven power brands across unrelated consumable categories; the dividend has been paid continuously since 1901; and no material litigation overhang is disclosed. The equity is genuinely permanent capital in a defensive category.

Recent News & Events

(Note: the third-party news feed returned no articles for CHD across the window from 2026-05-15, so this timeline is built from SEC filings, the earnings release and the earnings call rather than from a news aggregator.)

Has the business environment changed recently? Yes, in three respects since the prior report. Demand: better than planned — CHD’s categories grew 2.7% in consumption against a ~2% assumption, and CHD grew organic sales 5.8% on top, so the company is taking share in a slightly firmer market. Costs: worse than the headline — the Middle East framing is ~$30M for the year at an assumed ~$90/barrel crude (a lower oil assumption than the prior report’s $95–100 for the same dollar figure), but the gross burden flowing through the P&L is much larger, with $85.7M of inflation including Middle East commodity and transportation costs in Consumer Domestic alone in H1 and a −400bps manufacturing-and-logistics drag in the Q2 gross-margin bridge. Competition: more intense, and counter-intuitively so — promotional spend rose across the category (Henkel +1,100bps, P&G +200bps) at a time when high input costs would historically have suppressed it, which management attributes to tariff refunds being competed away.

Significant acquisitions? Yes — Miss Mouth’s Messy Eater, closed 2026-05-28 for ~$325M all-in (~4.1x FY2025 sales of ~$80M), financed with cash on hand and the company’s first commercial paper borrowings, and integrated on the North American ERP within roughly three months. Separately, the Touchland contingent earnout was written up to $158.7M and settled in cash in April 2026, completing that transaction at ~$870M all-in.

Change in accounting policies? None. The annual goodwill test was performed at the beginning of Q2 2026 and found fair value substantially in excess of carrying value for all reporting units. The indefinite-lived intangible review remains scheduled for the fourth quarter, which is when the Waterpik trade name will next be tested.

Recent changes — new markets, facilities, management? Management: stable — CEO Dierker (April 2025) and CFO McChesney (March 2025) are both in their second year, with no departures disclosed. Structure: the international M&A function was reorganised roughly 6–8 months ago from a centralised centre-of-excellence model to one where country management teams own deal sourcing, after which the company “filtered through 100 deals” and, in the CEO’s words, went “from first to third gear.” Systems: the North American ERP went live in April 2026, with further spend inside the ~$130M FY2026 capex plan; management is also pulling forward AI investment, funded from earnings over-delivery. Capacity: FY2026 capex includes manufacturing capacity investments for TheraBreath and Sterimar. Markets: international expansion of Touchland is targeted to begin contributing in 2027, subject to regulatory registration timelines. Compensation: the one-time 2030 Long Term Strategy Grant was made in January 2026, and the Strategic Initiatives metric was removed from the 2026 annual incentive plan.

APPENDIX B — Source Appendix

Church & Dwight Co., Inc. (NYSE: CHD) — Source Appendix

Supplemental to the report above. Report date: 2026-08-15. All sources are public and were accessed 2026-08-15/16 unless otherwise noted.

A. Primary Sources — SEC Filings (CIK 0000313927)

Note on the corpus. Refreshed this run via a bulk download of the company’s EDGAR filing history. Form 3/4/5 filings were downloaded as raw XML, which is what permitted the structured aff10b5One parse rather than an unreliable plain-text search for “10b5-1”. The integrity check passed, so the finding of exactly ten code-P purchases across five years is a genuine census and not an artifact of missing files.

B. Primary Sources — Company Communications

Transcript provenance. Retrieved from a public earnings-transcript source, which returned the Q2 FY2026 call stamped fiscal year 2026, fiscal quarter 2, dated 2026-07-31. The body was checked against the metadata and against the earnings release before quotation; both agree. Every direct quotation in this report and appendices is verbatim from this transcript.

C. Quantitative Data Sources

D. Prior Work and Peer Comparables

E. Data-Quality Notes, Corrections and Caveats

1. Transcript sourcing. The current quarter’s earnings call was obtained in full from a public transcript source and read end to end; every direct quotation is verbatim from it.

2. The third-party news feed returned no articles for CHD across the window from 2026-05-15. The recent-events timeline and the “Recent News & Events” diligence section were therefore rebuilt from 8-Ks, the 10-Q, the earnings release and the call, rather than from a news feed.

3. The aggregator’s TTM row for the period ending 2026-06-30 is largely null across the income statement, balance sheet and enterprise-value objects — only shares outstanding and a handful of fields populate. Every TTM-derived valuation figure in this report is therefore hand-built from the 10-Q (TTM sales ≈ $6,229M and TTM EBITDA ≈ $1,347M, each rolled from FY2025 for the H1 delta) and is labelled approximate. The EV of ~$26.0B is computed directly: 237,136,902 shares × $101.30, plus $2,256.2M of total debt, less $254.8M of cash.

4. Vendor identifier note. The fundamentals provider requires an exchange-qualified identifier (NYSE:CHD).

5. Correction to the prior report — ROE. The 2026-06-14 memo showed an FY2025 ROE of 10.8% in its margins-and-returns table. That figure does not reconcile: FY2025 net income of $736.8M against average common equity of ~$4.0–4.2B is ~17–18%, and the aggregated data reports 17.62%. The corrected series is used throughout this report. The FY2025 ROIC of ~13.0% in the prior report was correct and is unchanged.

6. Correction to the prior report — the peer premium. The 2026-06-14 memo stated that CHD’s ~18x EV/EBITDA was a premium to Colgate (~16x), P&G (~15x) and Clorox (~11x). On same-date TTM data to 2026-06-30, Colgate trades at 21.2x — above CHD’s ~19.3x — with P&G at 16.0x and Clorox at 15.1x. The cohort re-rated. CHD is now mid-pack, and this report says so.

7. Derived figures, explicitly flagged. Q3 FY2025 adjusted EPS of ~$0.809 is inferred from management’s statement that the ~$0.89 Q3 FY2026 guide represents “approximately 10% growth versus last year”; the Q4 FY2025 base of ~$0.87 is the residual from FY2025’s reported $3.53 less the three known quarters. The implied Q4 FY2026 range of $1.01–$1.08 follows arithmetically from the +6–8% full-year guide less H1 actual less the Q3 guide. The company has published no quarterly adjusted-EPS bridge, so these are derived, not disclosed.

8. Competitor promotional figures are management assertions. The Henkel +1,100bps, P&G +200bps and category +200bps promotional-spend changes were stated by CHD’s CEO on a public call and are not independently verified. They are attributed as such throughout.

9. Touchland brand-level financials are not disclosed. CHD does not report revenue by brand. The “high single digits” growth characterisation is a verbal answer on the call with no supporting figure, and cannot be tested against the ~$115M 2024 acquisition-year base.

10. Insider-sweep methodology. The 10b5-1 determination was made by parsing the structured <aff10b5One> XML element in each mirrored Form 4, not by a plain-text search — a text scan is unreliable because the flag is a checkbox field rather than prose. Transaction codes were counted across all non-derivative transactions in all 1,044 Form 4s: A 170, M 119, S 116, F 88, G 14, P 10, D 5. Every 2026 code-S filing was additionally checked for a paired code-M line, which is why this report characterises 2026 selling as mechanical exercise-and-sell rather than as a bearish signal.

11. Contradiction logged between management commentary and the financials. Management characterised the quarter as strong and noted that “a lot of our peer groups are going backwards on margin” while CHD expands. Both halves are accurate at the gross margin line (+40bps adjusted). At the operating line CHD’s own adjusted profit fell 9.1% and adjusted EPS fell 5.3%. This report states both facts side by side rather than adopting either framing.

12. No position. The author holds no position in CHD and none is assumed anywhere in this report.